Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics

Clinical and Translational Oncology

Volumn 15, Issue 2, 2013, Pages 132-138

  Wan, Liyan ^a   Li, Xiao ^a   Shen, Hong ^a   Bai, Xiaoyan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

EZH2; Image analysis; Immunohistochemistry; Lung cancer

Indexed keywords

TRANSCRIPTION FACTOR EZH2;

ADULT; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SMOKING HABIT; TISSUE MICROARRAY; TUMOR VOLUME;

EID: 84878548632     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0897-9     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
2. Hobert O, Jallal B, Ullrich A (1996) Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 16:3066-3073
3. Kuzmichev A, Margueron R, Vaquero A et al (2005) Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 102:1859-1864
4. Cao R, Zhang Y (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14:155-164
5. Margueron R, Li G, Sarma K et al (2008) Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 32:503-518
6. Chang CJ, Hung MC (2012) The role of EZH2 in tumour progression. Br J Cancer 106:243-247
7. Yaswen P (2010) HDAC inhibitors conquer polycomb proteins. Cell Cycle 9:2705
8. Vire E, Brenner C, Deplus R et al (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874
9. Kondo Y, Shen L, Cheng AS et al (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40:741-750
10. Choi JH, Song YS, Yoon JS, Song KW, Lee YY (2010) Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS 118:196-202
11. Hinz S, Kempkensteffen C, Christoph F et al (2008) Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J Cancer Res Clin Oncol 134:331-336
12. Panousis D, Patsouris E, Lagoudianakis E et al (2011) The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors. Eur J Gynaecol Oncol 32:156-159
13. Bachmann IM, Halvorsen OJ, Collett K et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268-273
14. Kikuchi J, Kinoshita I, Shimizu Y et al (2010) Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 116:3015-3024
15. Travis WD, Garg K, Franklin WA et al (2006) Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 1:S13-S19
16. Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285
17. Bai XY, Shen H (2006) Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray. Nan Fang Yi Ke Da Xue Xue Bao 26:1423-1426
18. Shen H (1994) Study on quantitative method of intensity of immunohistochemical staining (II). J Cell Mol Immunol 10:33-35
19. Shen H (1995) Study on quantitative method of immunochemical staining (III). Chin J Histochem Cytochem 4:89-92
20. Shen H, Lu YD (1993) Study on quantitative method of immunochemical staining. J Biomed Eng 10:281-284
21. Breuer RH, Snijders PJ, Smit EF et al (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736-743
22. Wang H, Albadine R, Magheli A et al (2012) Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol 30(4):428-433
23. Huqun Ishikawa R, Zhang J et al (2011) Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 118:1599-1606
24. Findeis-Hosey JJ, Huang J, Li F et al (2011) High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. Hum Pathol 42:867-872
25. Wang C, Liu X, Chen Z et al (2011) Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma. Mol Carcinog. doi: 10.1002/mc.21848
26. Yang X, Karuturi RK, Sun F et al (2009) CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 4:e5011
27. Cao Q, Yu J, Dhanasekaran SM et al (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27:7274-7284
28. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A (2004) Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 23:4930-4937
29. Athanassiadou AM, Tsipis A, Patsouris E et al (2011) Enhancer of zeste homologue 2 expression in breast carcinoma smears in relationship with p53, Ki-67 and other prognostic parameters. Acta Cytol 55:180-186
30. Testoni B, Schinzari V, Guerrieri F et al (2011) p53-paralog DNp73 oncogene is repressed by IFNalpha/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. Oncogene 30:2670-2678
31. Zhang YB, Niu HT, Chang JW, Dong GL, Ma XB (2010) EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines. Eur J Cancer Care (Engl) 20:106-112
32. Bracken AP, Pasini D, Capra M et al (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323-5335
33. Chang CJ, Yang JY, Xia W et al (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19:86-100